Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I was poking about for anything new re 737 and came across this research paper with an acceptance date of 11th May '24, "CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and CCNE1 amplified ovarian cancer".
(Apologies if C79 or A N Other posted anything linked to this last year.)
https://doi.org/10.1016/j.isci.2024.109978
The work must have been done around the time 737 was being handed back and 3 of the contributors were with Sierra at the time (Chris Hassig is now with Boundless Bio and from what I could find, Bryan Strouse is/was Global Scientific Director at GSK). If you look at the declaration of interests on page 11 you'll see people with links to GSK, Roche, AstraZeneca, Takeda and Boehringer Ingelheim (amongst others). These are all companies with deep pockets and staff who have awareness of 737.
It can't be too much longer until 737 surfaces and we find out who has it and what their plans are.
I forgot to mention that Boundless Bio used to be a private US firm until they listed on the NASDAQ in April so perhaps the shares included as part of the license deal were added as they knew they were going to go public (assuming of course if Boundless is the pharma).
https://www.google.com/finance/quote/BOLD:NASDAQ
HBD, agree its really intriguing on 737, transparency on this plus an Australian update are key levers to improving the SP further. GLA
Good morning HBD, I trust you are well along with all genuine holders/posters :)
Boundless were discussed here a good while back along with a certain Mr C. Hassig. - Like you, I felt they were potentially intertwined with taking CCT245737/SRA737 forwards having seen the molecule in action whilst at Sierra. However they have their own CHK1i molecule(s) BBI-335 and BBI-098 - whether or not CCT245737 is more effective though is the question I guess. Would a firm take on a better molecule than their own if the cost was low enough... taking a competitor out of the equation and/or improving ones own stable... hmmmm pondering the imponderables again!
So much is unknown as far as we are concerned; a brief US Patent search throws up the usual suspects:
Published yesterday - Boundless Bio patent application from March 2022 makes mention of CCT245737 among other CHK1i's(& plenty of other molecules as is the usual case) - https://patents.justia.com/patent/20240158383
Hassig joined Boundless in late 2019 - we can make timelines fit as always.
As an aside and clutching at straws somewhat - this patent was also published yesterday, private company, Edison Oncology:
"Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases"
CHK1 inhibitors get a mention along with many many other potential treatment combinations... but only Prexasertib is named - one way to keep SRA737/CCT245737 out of the direct search results..... who knows.
All the very best.
Hi C79 - I'm doing fine, thanks for asking. I was almost at breakeven here earlier in the week but for the moment I'm just snorkelling beneath the surface - still underwater but breathing air!
Re 737, what would be helpful to know is if the new license holder has changed its name. At least that might give us something new to go on.
Regards.
I still think that the unnamed pharma has taken on 737 to get it ready for sale. They will put a data package together and tout it around all the major pharma. I also think some of the team behind this are from Sierra 737 team. The 500k shares are a big clue for me. Problem is we don't know how many shares the unlisted has in total. Im sure ICR have some experienced deal makers and hopefully they have just given it away. A small, successful P2a combo trial and 737 will have a 800 million valueation. SAR would potentially get 27% of that. One thing though, in terms of good news, 737 isn't factored into SP, IMO. on the flip side, bad news and the Mm's would slaughter us. 🤷🏻♂️
I think SP may start to bounce and recover now
Hi Potnak - whilst your 'repackaged for selling on' theory is reasonable, surely Sar/CPF would have been able to put together all the data required to maximise its appeal for onward development? Sierra had already completed PI/II trials so wouldn't that mean 737 is effectively P3-ready in respect to combo trials with Gemcitabine and/or Cisplatin? Hmmmm, all just mysteries of the bleedin' universe.
Some info for anyone new here wondering what's going on with 737 -
"Under the terms of the Licensing Agreement, an immediate upfront payment of US$0.5 million is due to CPF. An additional fee made up of up to US$1.0 million cash and 500,000 shares in the Licensee Company (the "Consideration Shares") may be payable upon the sooner of 12 months following the signing of the Licensing Agreement, or the event of the Licensee Company achieving certain commercial and material financing objectives. A further announcement regarding any future income, including any Consideration Shares which may be issued, will be made at the appropriate time.
Additional payments to the aggregate amount of up to US$289 million may become payable to CPF under the Licensing Agreement, subject to achievement of certain development, regulatory and commercial milestones which may or may not be achieved. The Licensee Company will also pay tiered high single digit royalties to CPF on the net sales of any product successfully developed and commercialised.
Under the terms of Sareum's co-development agreements with CPF and Cancer Research Technology Ltd, Sareum is entitled to receive 27.5% of any income arising from this licensing of the SRA737 programme. Therefore, Sareum is entitled to receive US$137,500 from the upfront fee payable under the Licensing Agreement, as well as 27.5% of any future payments payable by the Licensee Company (including any Consideration Shares received), under the terms of the Licensing Agreement."
737 is the dark horse in all of this. I would welcome an update to understand what has been going on. Considering the Rns was January, worst case we’ll be waiting for end of the year for any payments and update. Unless of course it gets commercialised. Given we’re nearing end of may, what realistically could of been done with 737 in that time frame?
Hi HBD. Essentially to use 737 in combo, they will need to treat it as a Phase 1 study. Whether double or triple combo. All compounds might be, individually proven to be safe but when taken together they could cause issues. That will need yo be trialed. Trials cost money and I guess ICR don't want to pay. I'm thinking the unnamed pharma will gather all data, including from the combo candidates, package that up then either raise cash to progress,sell on or maybe do a combo 1a before jumping straight into phase 2. I still have my doubts about 737, if it was really that good why has ICR given to 1 relatively unknown pharma (pronai) and now an unnamed pharma. The terms of the deal mean nothing without knowing how many shares the new company has in issue. If gets P2 combo, its worth 800 million IMO.
Hi Potnak - they'd only need to return to a P1 study if 737 was being used with compounds other than Gemcitabine or Cisplatin. If the next trial is a continuation of the work carried out by Sierra then they're already some way down that particular road.
https://clinicaltrials.gov/search?term=NCT02797977
Time for a very long walk in the sunshine....
Hi potnak. Surely we all judge our CHK1 on the data shown and that has been. Amazing....surely you agree? Siera will ecstatic about it before they got involved with mono...
I go by the data shown and the untreatable cancers it has shown great data in ...and also the scientists and Dr involved with it.
Surely you agree with above? The problem could be that combo or triple therapy needed but it works and it works great and umet needs
The data may look good but why isn't pharma knocking on ICR's door. Surely they've seen the data? I honestly think this unnamed company is gathering all the work and data collected so far and putting into a saleable package and I think the original Sierra team are behind it. It might even be a new company set up for this very reason. I'm not being negative but you all have to admit. For such a promising compound, it's weird that it isn't being snapped up and shouted about
Hi potnak. Thanks for reply. The fact original team back, speaks volumes. Hope it goes for a fair value and we get a good amount for all that hard work.
Matter of time hopefully
Potnak l don't have to admit anything, especially for finding it weird that 737 in not being snapped up and shouted about.
A pharma may well wish to remain out if the limelight.
Pharma industry very competitive.
You can either make your own product better or damage or undermine your competitors.
When GSK took over SO they announced they had achieved their major goal, that being purchase of Momoletonib.
By inferral, what was their non major objective?
Would 737 in combo prove serious competition to the GSK pipeline especially with tegardsto urgent areas of unmet need, of which HGSOC along with SCLC/NSCLC and indeed breast cancer.
From memory GSK was the first into Eupope with their pipeline for treating these Indications and hyped up BS about how much benefit it will be to the patients. Their pipeline was fast tracked.
It were approved around early 2022 as a treatment in some of the above Indications.
The European medical Agency developed concerns as to regards the safety of these compounds, whereby as a result there was a reduced maximum dose and in addition to be kept under close scrutiny for increased adverse events.
GSK now have their foot in the door of approaching a billion dollar a year turnover for their therapies in Europe alone. Treatment regime is/was/planned for 2 to 5 years.
That is a serious amount of revenue that would over this period of time pay back what they had paid for the Tesaro pipeline.
Without having to admit that the above timeliness and events around appear a tad more than coincidental, giving GSK's past of illegal practices and making false statements for which they have paid billions in fines and compensation, would it therefore be beyond belief that
1. GsK had no need for 737.
2 GSk would do in whatever manner they deemed relevant, make the on license of 737 either not available or long term delay?
Why would Stephen Dilley resign?
A years salary and perks reaching over a million dollars. He did not work the year, in effect it was nigh instant.
There really is a lack of integrity nowadays among all forms of professions.
If they cannot buy you they will seek to destroy you. Conform to what the masters of the world want or suffer. Those at the bottom will suffer supporting the greed of those at the top.
I agree with your observations SOG. A CEO of a bought out company that has been sold is sometimes a required to commit to not starting or joining a company in the same area. This was all about maximising revenue for GSK and taking a company with a competitive product out would have served their interest well. Patients be dammed. Hopefully CHK1 is with a serious and well funded pharma.
Thankyou for the reminder of that fearg. I remember many years ago around 35 having to sign paperwork agreeing similar.
Much would depend on Stephen Dilleys letter of resignation.
However their are ways around this, but one has to be extremely careful.
Such conditions may be put as 'either yourself, wife, relative of the family' just to begin with.
There may even be stipulation of any product or intellectual property, either now or in the past that are placed as conditions.
In this instance it would be beneficial to be kept quiet. But if Potnak is right in his belief that, former Sierra employee or employees are involved then anonymity would be both prudent and give credibility.
The new private company has taken up from where SO left off.
Now why would an unknown pharma take on an on licence to nigh exact terms as to original contract?
My instincts are with previous CEO Nick Glover a staunch advocate of CHK1.
I think Nick Glover resigned too as he was l believe a tad peeved on cessation of development of 737.
Regards